Implant Or Insert Patents (Class 424/422)
  • Patent number: 11000627
    Abstract: The present invention relates to a process of treating an implant, comprising a step of treating the surface of the implant with at least one phosphonic acid compound or a pharmaceutically acceptable salt, ester or amide thereof under sonication at a temperature of about 50° C. to about 90° C. This process is highly advantageous in that it allows the formation of a monolayer of the phosphonic acid compound on the implant surface, having a particularly dense surface coverage which, in turn, results in an improved implant biocompatibility and improved osseointegration.
    Type: Grant
    Filed: February 13, 2017
    Date of Patent: May 11, 2021
    Assignee: NANO BRIDGING MOLECULES SA
    Inventors: Sabrina Buchini, Richard Curno, Björn-Owe Aronsson, Péter Péchy
  • Patent number: 10993919
    Abstract: Compositions and methods are disclosed herein to deliver and anchor nanoscale drug carriers into the extracellular matrix (ECM) of tissues, such as degenerating cartilage or tumor margins, and to provide local and sustained release of drugs.
    Type: Grant
    Filed: October 3, 2017
    Date of Patent: May 4, 2021
    Assignee: University of Florida Research Foundation, Inc.
    Inventors: Blanka Sharma, Shannon B. Brown
  • Patent number: 10961501
    Abstract: A system for seeding therapeutic active ingredients (TAIs) onto a porous scaffold includes a first chamber for accommodating the scaffold, a TAI storage device for storing TAIs, at least one second chamber for storing TAI media, and a gas inlet for receiving gas from a compressed source. A flow circuit is coupled to the first chamber, the TAI storage device, the second chamber and the gas inlet for delivering the TAIs, the TAI media and the gas to the scaffold. A pump pumps at least one of the TAIs, the TAI media and the gas in the flow circuit. The system also includes a processor that regulates the delivery of the TAIs, the TAI media and the gas to the scaffold via a plurality of valves.
    Type: Grant
    Filed: April 9, 2018
    Date of Patent: March 30, 2021
    Assignee: EpiBone, Inc.
    Inventors: Sarindr Bhumiratana, Keith Yeager
  • Patent number: 10953135
    Abstract: Disclosed herein are tissue scaffold materials with microspheres of one density embedded in hydrogel of a different density. The disclosed materials have improved ability to facilitate cellular invasion and vascularization for wound healing and tissue regeneration. The inventors have found that materials having components with different densities promotes invasion of cells, including desirable cells such as fibroblasts and endothelial precursor cells, into the scaffold.
    Type: Grant
    Filed: April 12, 2018
    Date of Patent: March 23, 2021
    Assignee: Cornell University
    Inventors: Jason Spector, Abraham D. Stroock, John Morgan
  • Patent number: 10945997
    Abstract: An object of the invention is to obtain a preparation which shows enhanced effectiveness and safety compared to tacrolimus, has the concentration in blood maintained at a constant level without individual differences, whereby the control of the amount of administration depending on the blood kinetics (blood trough concentration) becomes unnecessary. The present invention relates to a polymeric derivative of tacrolimus, in which a polyethylene glycol segment and an alcoholic hydroxy group of tacrolimus are bonded to side-chain carboxy groups of a polyaspartic acid derivative.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: March 16, 2021
    Assignee: Nippon Kayaku Kabushiki Kaisha
    Inventors: Nao Yoneki, Akihiro Sekiguchi, Kana Mizunuma, Yuki Kobayashi, Junpei Konno, Kan Saiga, Keiichirou Yamamoto
  • Patent number: 10947282
    Abstract: Embodiments of the invention are directed to Ubx-fusion molecules that maintain their mechanical strength and properties even after being fused with Ubx. Ubx fusions with VEGF and other growth factors, cell signaling proteins, and cell binding proteins can be used to induce angiogenesis. Ubx fibers and mesh, embedded within a tissue engineering scaffold, induce formation of vasculature within the scaffold. The presence of vasculature is necessary to provide oxygen and nutrients to other cells growing within the scaffold.
    Type: Grant
    Filed: January 20, 2016
    Date of Patent: March 16, 2021
    Assignees: The Texas A & M University System, William Marsh Rice University
    Inventors: Sarah Bondos, Kayla Bayless, Kathleen Matthews, Jan Patterson, Colette Abbey, David Howell, Hao-Ching Hsiao, Kelly Churion, Shang-Pu Tsai, Sandhya Ramasamy, Dustin Porterpan, Keira Northern
  • Patent number: 10940157
    Abstract: The present disclosure relates to a vaginal system that prevents pregnancy comprised of segesterone acetate and ethinyl estradiol and is configured for thirteen 28-day product-use cycles.
    Type: Grant
    Filed: March 10, 2020
    Date of Patent: March 9, 2021
    Assignee: The Population Council, Inc.
    Inventor: Bruce Variano
  • Patent number: 10933174
    Abstract: An anchorage device is provided that is configured to surround an implantable medical device. The anchorage device includes a substrate having a hemostatic agent and an active pharmaceutical ingredient selectively positioned on the substrate. Kits, systems and methods are disclosed.
    Type: Grant
    Filed: May 1, 2017
    Date of Patent: March 2, 2021
    Assignee: MEDTRONIC, INC.
    Inventors: Satish Pulapura, Fatima Buevich, Jorie S. Soskin, Franklin R. Mansfield, Kai R. Worrell, Charlie Wood, Jorge Alberto Trevino Blanco
  • Patent number: 10932465
    Abstract: The invention relates to an antimicrobial mixture containing 4-(3-ethoxy-4-hydroxy-phenyl)butan-2-one and an additional compound chosen from chlorhexidine digluconate, chlorhexidine hydrochloride and a polyhexamethylene biguanide salt, and also to a cosmetic composition containing such a mixture. Use in caring for, making up and cleansing keratin materials.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: March 2, 2021
    Assignee: L'OREAL
    Inventors: Julien Galvan, Sylvie Cupferman, Gael Malet
  • Patent number: 10925882
    Abstract: The present disclosure relates to a vaginal system that prevents pregnancy comprised of segesterone acetate and ethinyl estradiol and is configured for thirteen 28-day product-use cycles.
    Type: Grant
    Filed: March 23, 2020
    Date of Patent: February 23, 2021
    Assignee: The Population Council, Inc.
    Inventor: Bruce Variano
  • Patent number: 10918649
    Abstract: The present disclosure relates to a vaginal system that prevents pregnancy comprised of segesterone acetate and ethinyl estradiol and is configured for thirteen 28-day product-use cycles.
    Type: Grant
    Filed: June 21, 2019
    Date of Patent: February 16, 2021
    Assignee: The Population Council, Inc.
    Inventor: Bruce Variano
  • Patent number: 10881622
    Abstract: Technologies are described for delivery of compounds to aid in weight management. A transdermal microdispenser based system may deliver weight management compounds through the time and dose specific administration of appetite suppression, metabolic enhancers, and satiation compounds. The transdermal delivery system may be controlled based on data associated with subject such as calorie intake, physical activity, satiation, and hunger. The system may be integrated with medical monitoring or fitness tracking systems. Delivery of the compounds may be distributed over the course of a day at selected or adjusted doses to be safe and effective for their specific modality. For example, appetite suppressants may be delivered during periods of the day when cravings occur, satiation compounds may be delivered to coincide with meals, and metabolic stimulators may be delivered at times to optimally increase metabolism based on caloric balance. Control factors may also be predictive to prevent the onset of hunger.
    Type: Grant
    Filed: September 17, 2018
    Date of Patent: January 5, 2021
    Assignee: Xinova, LLC
    Inventors: Michael Keoni Manion, Stephanie Brunelle
  • Patent number: 10881619
    Abstract: In one aspect, the present disclosure provides microparticles that are configured to release a first drug over a first time period and to release a second drug over a second time period, wherein a lag period of substantially no drug release occurs between the first and second time periods. In other aspects, the present disclosure pertains to the use of such microparticles in delivery systems and methods of treatment. In another aspect, the present disclosure pertains to drug delivery systems that comprising a folded inflatable drug delivery balloon that comprises folds and microparticles positioned within the folds.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: January 5, 2021
    Assignee: Boston Scientific Scimed, Inc.
    Inventors: Javier Palomar-Moreno, Michelle Hannon, Phillip Bannister
  • Patent number: 10881695
    Abstract: An autologous cell therapy product composed of fibroblasts grown for each individual to be treated for vocal cord scarring. The suspension of autologous fibroblasts, grown from a biopsy of each individual's own buccal mucosa or skin using current good manufacturing practices (CGMP) and standard tissue culture procedures, is supplied in cryovials containing cryopreserved autologous fibroblasts or precursors thereof, at a concentration of between 1.0×107 cells/mL and 2.7×107 cells/mL, wherein at least 85% of the human fibroblast cells are viable after freezing and thawing.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: January 5, 2021
    Assignee: Fibrocell Technologies, Inc.
    Inventor: John Maslowski
  • Patent number: 10881537
    Abstract: The present invention relates generally a manufacturing process which results in a completely hydrogel polymer device that maintains lumen patency which allows for numerous applications. Catheters and stents are particular examples, and their composition, mechanical characteristics, and the significantly unique ability to conduct and allow fluids to pass from one end to the other without physiological rejection, inflammation, or manifestation of complications due to implant or otherwise undesirable outcomes when used for ambulatory and or therapeutic interventions is the purpose of the invention.
    Type: Grant
    Filed: October 13, 2015
    Date of Patent: January 5, 2021
    Inventor: Scott M. Epstein
  • Patent number: 10881501
    Abstract: Allografts for soft tissue repair, including breast reconstruction and other plastic surgery procedures, are disclosed. One allograft is made from decellularized dermal tissue and constitutes a collagen matrix having substantially uniform density and porosity. Another allograft is a hybrid bilayer tissue form that is made from decellularized dermal and adipose tissues. Methods for making both allografts are also disclosed.
    Type: Grant
    Filed: January 10, 2019
    Date of Patent: January 5, 2021
    Assignee: Musculoskeletal Transplant Foundation
    Inventors: Michael Locarno, Bryan Choi, Manh-Dan Ngo
  • Patent number: 10874108
    Abstract: A metal-EDTA compound/complex for combatting biofilms and/or treating wounds. The compound/complex comprises EDTA and from two to four metal ions. Of those two to four metal ions, at least two are different metal ions selected from Ag, Al, Au, Ba, Bi, Tl, Ce, Co, Cu, Fe, Ga, Ir, Mo, Rh, Ru, Ti, and Zn ions. The metal-EDTA compound/complex may exhibit any one or more of anti-microbial, anti-biofilm and anti-inflammatory activities in use and may increase the susceptibility of a biofilm and the microorganisms within said biofilm to attack by anti-microbial agents, helping to remove and sanitise the biofilm. A composition, wound dressing and medical device comprising the metal-EDTA complex are also provided. Uses of the metal-EDTA compound/complex as a medicament and/or to sanitise and/or substantially remove a biofilm from a substrate are also disclosed.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: December 29, 2020
    Assignee: 5D Health Protection Group Ltd.
    Inventors: Steven Percival, Rui Chen, John Alan Hunt
  • Patent number: 10869948
    Abstract: Disclosed is a composition of a collagen peptide and an elastin peptide, method of producing the same and use thereof. The composition of the present disclosure consists of a collagen peptide and an elastin peptide; the collagen peptide is prepared by enzymatic hydrolysis of a collagen material with pepsin or trypsin, and the elastin peptide is prepared by enzymatic hydrolysis of an elastin material with papain and/or protease Protamex. In the present disclosure, an elastin peptide and a collagen peptide with molecular weight in a specific range are prepared by specific processes, and the composition composed of the two at a suitable ratio can simultaneously and significantly increase the amount of the elastin and collagen in a damaged skin in a small usage amount, and significantly increase the content of hyaluronic acid and hydroxyproline while decrease the content of MMP3, meanwhile, inhibit skin inflammatory factors.
    Type: Grant
    Filed: May 16, 2019
    Date of Patent: December 22, 2020
    Assignee: INFINITUS (CHINA) COMPANY LTD.
    Inventors: Huawei Zhu, Xiaoling Wang, Liugang Ding, Xiaolei Guo, Yazhong Ge
  • Patent number: 10869947
    Abstract: Hydrogel compositions are provided (a) that have a continuous hydrophobic phase and a discontinuous hydrophilic phase, (b) that have a discontinuous hydrophilic phase and a continuous hydrophilic phase, or (c) that are entirely composed of a continuous hydrophilic phase. The hydrophobic phase, if present, is composed of a hydrophobic polymer, particularly a hydrophobic pressure-sensitive adhesive (PSA), a plasticizing elastomer, a tackifying resin, and an optional antioxidant. The discontinuous hydrophilic phase, if present, is composed of a crosslinked hydrophilic polymer, particularly a crosslinked cellulosic polymer such as crosslinked sodium carboxymethylcellulose. For those hydrogel compositions containing a continuous hydrophilic phase, the components of the phase include a cellulose ester composition or an acrylate polymer or copolymer, and a blend of a hydrophilic polymer and a complementary oligomer capable of hydrogen bonding thereto.
    Type: Grant
    Filed: April 29, 2014
    Date of Patent: December 22, 2020
    Assignees: Corium, Inc., A.V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences
    Inventors: Gary W. Cleary, Shoreh Parandoosh, Mikhail M. Feldstein, Anatoly E. Chalykh, Nicolai A. Platè, Valery G. Kulichikhin
  • Patent number: 10864304
    Abstract: A material including a plurality of fatty acid chains cross-linked together and a silver fatty acid salt formed with the fatty acid chains within the material. Methods for forming a material are also included. The silver-containing materials can be utilized alone or in combination with a medical device for the release and local delivery of one or more anti-infective agents.
    Type: Grant
    Filed: May 19, 2014
    Date of Patent: December 15, 2020
    Assignee: ATRIUM MEDICAL CORPORATION
    Inventors: Keith M. Faucher, Hilda N. Rono, Anthony Richard Horton, Jocelyn Choroszy, Paul Martakos
  • Patent number: 10847363
    Abstract: Methods are provided for selective film deposition. One method includes providing a substrate containing a dielectric material and a metal layer, the metal layer having an oxidized metal layer thereon, coating the substrate with a metal-containing catalyst layer, treating the substrate with an alcohol solution that removes the oxidized metal layer from the metal layer along with the metal-containing catalyst layer on the oxidized metal layer, and exposing the substrate to a process gas containing a silanol gas for a time period that selectively deposits a SiO2 film on the metal-containing catalyst layer on the dielectric material.
    Type: Grant
    Filed: November 16, 2018
    Date of Patent: November 24, 2020
    Assignee: Tokyo Electron Limited
    Inventor: Kandabara Tapily
  • Patent number: 10842913
    Abstract: Tissue repair and restoration can be performed using an elastic material formed from tropoelastin. The elastic material can be formed by providing a solution of tropoelastin monomers, applying the solution to a surface, and heating the solution on the surface in absence of a cross-linking agent to enable the tropoelastin monomers to bind to each other to form an elastic material that does not dissociate into tropoelastin monomers when the elastic material is contacted with an aqueous solution.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: November 24, 2020
    Assignee: ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED
    Inventors: Anthony Steven Weiss, Suzanne Marie Mithieux
  • Patent number: 10821182
    Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
    Type: Grant
    Filed: May 6, 2020
    Date of Patent: November 3, 2020
    Assignee: AXSOME THERAPEUTICS, INC.
    Inventor: Herriot Tabuteau
  • Patent number: 10813763
    Abstract: An implantable mesh including demineralized bone fibers mechanically entangled into a biodegradable or permanent implantable mesh is provided. A method of preparing the implantable mesh is also provided. The method of preparing the implantable mesh includes mechanically entangling demineralized bone fibers with non-bone fibers to form the implantable mesh. The mechanical entanglement of the bone fibers into the implantable mesh is achieved by applying needle punching with barbed needles, spun lacing, entanglement with water jets or air jets or ultrasonic entanglement with ultrasonic waves. A method of implanting an implantable mesh at a target bone tissue site is also provided.
    Type: Grant
    Filed: July 26, 2016
    Date of Patent: October 27, 2020
    Assignee: Warsaw Orthopedic, Inc.
    Inventor: Kelly W. Schlachter
  • Patent number: 10800708
    Abstract: The object of the present invention is to provide an antibacterial material capable of sustaining antibacterial properties for a long time. The object can be solved by a silver-containing calcium phosphate sintered body having silver particles therein, wherein an average particle diameter of the silver particles is 0.01 to 0.5 ?m.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: October 13, 2020
    Assignees: TOKYO INSTITUTE OF TECHNOLOGY, KYOCERA CORPORATION
    Inventors: Toshiyuki Ikoma, Tomoaki Sugiyama, Hiroaki Igashira, Yugo Fukuyama, Michimasa Kamo, Masayuki Kyomoto, Takashi Sasaki
  • Patent number: 10799611
    Abstract: The present invention relates to a dry composition, which upon addition of an aqueous medium forms a substantially homogenous paste suitable for use in haemostasis procedures. The paste forms spontaneously upon addition of the liquid, hence no mechanical mixing is required for said paste to form. The invention further relates to methods of preparing said dry composition, a paste made from said dry composition and use of said paste for medical and surgical purposes.
    Type: Grant
    Filed: April 26, 2018
    Date of Patent: October 13, 2020
    Assignee: Ferrosan Medical Devices A/S
    Inventor: Kristian Larsen
  • Patent number: 10792029
    Abstract: A bone suture assembly including a flexible generally cylindrical sleeve, a plurality of lengths of suture extending through the generally cylindrical sleeve, and at least one sleeve securing thread associated with the generally cylindrical sleeve. A bone suture retaining method including engaging a suture with a bone engaging sleeve, inserting the suture and the bone engaging sleeve engaged thereby into a transosseous tunnel formed into a bone by pulling the bone engaging sleeve into the transosseous tunnel and retaining the suture and the bone engaging sleeve in the transosseous tunnel by virtue of the bone engaging sleeve being unable to fit through an aperture in the bone.
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: October 6, 2020
    Assignee: MININVASIVE LTD.
    Inventors: Boaz Harari, Mordehai Sholev, Ronen Raz, Arnon Mousaiuf, Dror Rosner, Paul Mraz
  • Patent number: 10787485
    Abstract: The invention relates to a peptide comprising (i) a main chain comprising at least one L-3,4-dihydroxyphenylalanine (DOPA), (ii) at least one integrin binding peptide, and (iii) at least one heparin binding peptide. The invention further relates to a coating for metal surfaces comprising the peptide according to the invention and a coated metal surface which promotes osseointegration that can be obtained by reacting the peptide according to the invention with a metal surface.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: September 29, 2020
    Assignee: Universität
    Inventors: Annette Beck-Sickinger, Mareen Pagel, Rayk Hassert
  • Patent number: 10773062
    Abstract: Methods and devices to affect types, proportion, quantity, distribution, or proliferation of microorganisms within a female reproductive system.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: September 15, 2020
    Assignee: Nine Medical, Inc.
    Inventors: Benjamin Kahn Cline, Ryan Kendall Pierce
  • Patent number: 10772716
    Abstract: A method for promoting healing of tissue by delivering a bioreactor into a subject is provided. The bioreactor is an enclosed housing with paracrine factor producing cells enclosed within the housing. The housing is impermeable to the paracrine factor producing cells, impermeable to immunological cells outside of the housing, and permeable to paracrine factors produced by the paracrine factor producing cells. The paracrine factors produced by the paracrine factor producing cells are released out of the housing to promote healing of the tissue.
    Type: Grant
    Filed: February 21, 2019
    Date of Patent: September 15, 2020
    Assignee: The Johns Hopkins University
    Inventors: Gary Gerstenblith, Jason Benkoski, George Coles, Chao-Wei Hwang, Peter Johnston, Gordon Tomaselli, Robert G. Weiss, Steven P. Schulman, Jeffrey A. Brinker
  • Patent number: 10758643
    Abstract: A medical product which contains a mechanophore, and the use of a mechanophore for producing a medical product.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: September 1, 2020
    Assignee: Aesculap AG
    Inventors: Kris Brosig, Michael Utz
  • Patent number: 10751417
    Abstract: Described herein are drug delivery systems for delivering biologically active agents comprising primary or secondary amines, or a ring nitrogen atom of an azaheteroaryl ring, pharmaceutically acceptable salts thereof, drug delivery reagents related thereto, pharmaceutical compositions comprising the drug delivery systems, and the use of the drug delivery systems as sustained release therapeutics.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: August 25, 2020
    Assignee: Novartis AG
    Inventors: Christopher M. Adams, Myriam April, Tanzina Fazal, Cornelia Jutta Forster, Edward Charles Hall, Cameron Chuck-munn Lee
  • Patent number: 10744110
    Abstract: The present invention provides methods and compositions for treating non-small-cell lung cancer (NSCLC) by administering a) a composition comprising nanoparticles that comprise paclitaxel and an albumin and b) a platinum-based agent (e.g., carboplatin), wherein the individual has diabetes, has four or more metastatic sites, and/or is at least about 70 years old.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: August 18, 2020
    Assignee: Abraxis BioScience, LLC
    Inventor: Neil P. Desai
  • Patent number: 10744233
    Abstract: Inventive concepts relate generally to the field of implantable urological devices, and more particularly to compositions that inhibit crystallization of urine components. Described are implantable urological devices including a surface and a crystallization inhibitor composition, the crystallization inhibitor composition including: (a) an inhibitor of urine component crystallization in combination with a biodegradable polymer, or a polyalkene homopolymer or copolymer, or (b) a biodegradable polymer that includes an inhibitor of urine component crystallization, wherein the crystallization inhibitor composition provides controlled release of the inhibitor of urine component crystallization from the surface of the device into a subject. Methods of making the implantable urological devices are also described.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: August 18, 2020
    Assignee: Innovative Surface Technologies, Inc.
    Inventor: Kristin Taton
  • Patent number: 10736994
    Abstract: A composite dura substitute implant for implantation at a dura defect site having a porous layer that provides an osteoconductive scaffold for bony ingrowth, a porous layer that provides a scaffold for regeneration of collagen at a dura surface, and an intervening layer for preventing cerebrospinal leakage is disclosed. The composite dura substitute implant facilitates regeneration of dura mater and promotes osteointegration with bony tissue. Methods of manufacturing such an implant and methods of treatment using such composite dura substitute implants are further disclosed.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: August 11, 2020
    Assignee: Beijing Bonsci Technology Co., Ltd.
    Inventors: Hongtao Nie, Kai Zhang
  • Patent number: 10729730
    Abstract: The described invention provides a method of functionally reprogramming adult cells to an immature cell type that expresses one or more embryonic biomarkers. The reprogramming is accomplished by contacting the adult cells with a platelet rich fraction comprising platelet-like cells from umbilical cord blood or peripheral blood, and expanding the immature cell type in vitro under culture conditions to generate an insulin-producing cell population that expresses human beta-cell specific transcription factors and is functionally equivalent to human pancreatic beta-cells. Without being limited by theory, platelet-like cells and their released mitochondria display immune tolerance-associated markers that may modulate the function and differentiation of immune cells.
    Type: Grant
    Filed: August 28, 2017
    Date of Patent: August 4, 2020
    Assignee: HACKENSACK UNIVERSITY MEDICAL CENTER
    Inventor: Yong Zhao
  • Patent number: 10729810
    Abstract: The present invention relates to novel bone compositions for locally delivering a therapeutic agent to the site of a bone defect. Therapeutic agents may promote repair of the bone defect and/or treat conditions or disorders such as pain, inflammation, cancer, and infection. The compositions include calcium phosphate cements and a demineralized bone matrix or a collagen sponge. The compositions are useful for implantation in a patient at the site of a bone defect.
    Type: Grant
    Filed: July 18, 2014
    Date of Patent: August 4, 2020
    Assignees: CAYMAN CHEMICAL COMPANY, INC, MYOMETRICS LLC
    Inventors: Stephen Douglas Barrett, Joseph Michael Colombo, Bradlee David Germain, Andriy Kornilov, James Bernard Kramer, Adam Uzieblo, Gregory William Endres, Fred Lawrence Ciske, Thomas Allen Owen, James Paul O'Malley
  • Patent number: 10723986
    Abstract: The invention provides systems, modules, bioreactor and methods for the automated culture, proliferation, differentiation, production and maintenance of tissue engineered products. In one aspect is an automated tissue engineering system comprising a housing, at least one bioreactor supported by the housing, the bioreactor facilitating physiological cellular functions and/or the generation of one or more tissue constructs from cell and/or tissue sources. A fluid containment system is supported by the housing and is in fluid communication with the bioreactor. One or more sensors are associated with one or more of the housing, bioreactor or fluid containment system for monitoring parameters related to the physiological cellular functions and/or generation of tissue constructs; and a microprocessor linked to one or more of the sensors. The systems, methods and products of the invention find use in various clinical and laboratory settings.
    Type: Grant
    Filed: December 30, 2016
    Date of Patent: July 28, 2020
    Assignee: OCTANE BIOTECH INC.
    Inventors: Timothy J. N. Smith, Sydney M. Pugh, Martin R. Pecaric, Rupert Hagg, Roberto Tommasini, Yves Larcher, Lowell D. Misener
  • Patent number: 10722443
    Abstract: Embodiments herein are directed to moisturizing compositions comprising interpenetrating polymer networks, methods of making moisturizing compositions and methods of using moisturizing compositions.
    Type: Grant
    Filed: February 13, 2017
    Date of Patent: July 28, 2020
    Assignee: RODAN & FIELDS, LLC
    Inventors: Kathy Ann Fields, Kathryn Pregerson Rodan, George Paul Majewski, Timothy John Falla, Dzung Q. Le
  • Patent number: 10709817
    Abstract: The invention relates to biocompatible, bioabsorbable derivatized non-crosslinked chitosan compositions optionally crosslinked to gelatin/collagen by 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC) for biomedical use and methods of making and testing such compositions, including a modified acute systemic toxicity test. The compositions comprise derivatized chitosan reacetylated to a degree of N-deacetylation (DDA) of between about 15% and 40%. The compositions are typically bioabsorbed in about 90 days or less and can be made to bioabsorb at differing rates of speed. The compositions are initially soluble in aqueous solution below pH 6.5. The compositions have an acid content that can be adjusted between about 0% (w/w) and about 8% (w/w) to customize the composition for uses that require and/or tolerate differing levels of cytotoxicity, adhesion, composition cohesion, and cell infiltration into the composition.
    Type: Grant
    Filed: February 13, 2018
    Date of Patent: July 14, 2020
    Assignee: Tricol Biomedical, Inc.
    Inventors: Barbara McGrath, Simon McCarthy, Sam Kuhn, Alysha Wold, Michael Stolten, Amanda Bennett
  • Patent number: 10702628
    Abstract: A biomaterial for the treatment of spinal cord or of peripheral nerve injury, obtainable by: a) treating a hyaluronic acid derivative with a coating solution promoting Neuronal Stem Cells adhesion, branching and differentiation; b) contacting isolated Neuronal Stem Cells with the hyaluronic acid derivative obtained from step a) and culturing and expanding the absorbed cells in the presence of growth or neurotrophic factors selected from ?FGF (basic fibroblast growth factor), CNTF (ciliary neurotrophic factor), BDNF (brain derived neurotrophic factor) and GDNF (glial derived neurotrophic factor) or mixtures thereof.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: July 7, 2020
    Assignee: ANIKA THERAPEUTICS S.R.L.
    Inventors: Alessandra Pavesio, Angelo Vescovi, Fabrizio Gelain, Maurizio Verga
  • Patent number: 10695400
    Abstract: The description provides compositions and methods for treating ETBR-related cancer. In certain aspects, the description provides a delivery system for the controlled, systemic release of at least one of ETBR antagonists, caspase-8 inhibitors, or a combination thereof, optionally including an ETAR antagonist, an anti-PD-1 antibody, a bRAF inhibitor, niacinamide or a combination thereof. The compositions described are useful for the treatment of certain cancers, including, e.g., breast cancer, malignant melanoma, squamous cell carcinoma, glioblastoma, as well as others. In addition, the description provides a delivery system for the controlled release of at least one of ETBR antagonists, caspase-8 inhibitors or a combination thereof, optionally including at least one of an ETAR antagonist, an anti-PD-1 antibody, a bRAF inhibitor, niacinamide, or a combination thereof, to the central nervous system that are useful for treating cancers that have spread to the brain.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: June 30, 2020
    Assignee: ENB THERAPEUTICS, INC.
    Inventor: Sumayah Jamal
  • Patent number: 10676556
    Abstract: A water-absorbing polymer obtained from polymerization of (A) and (B) in aqueous medium wherein (A) is a phosphate-containing (meth)acrylic monomer and/or a salt thereof, and (B) is a monomer having one (meth)acrylic group within the molecule and/or a salt thereof that is different from component (A); and reacting the reaction product of (A) and (B) with (C) an organopolysiloxane having a (meth)acrylic group at both ends.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: June 9, 2020
    Inventors: Fatemeh Mohammadi, Lisa Qu, Emi Akabane
  • Patent number: 10675298
    Abstract: Particles and related methods are disclosed.
    Type: Grant
    Filed: September 27, 2012
    Date of Patent: June 9, 2020
    Assignee: Boston Scientific Scimed Inc.
    Inventors: Janel L. Lanphere, John Spiridigliozzi, Orla McCullagh, Paul DiCarlo
  • Patent number: 10660868
    Abstract: The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions. following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment.
    Type: Grant
    Filed: July 20, 2016
    Date of Patent: May 26, 2020
    Assignee: Forest Laboratories Holdings Limited
    Inventors: Suneel K Rastogi, Niranjan Rao, Antonia Periclou, Wattanaporn Abramowitz, Mahendra G Dedhiya, Shashank Mahashabde
  • Patent number: 10653798
    Abstract: Embodiments of the present disclosure provide for electroactive supramolecular polymeric assemblies, methods of making electroactive supramolecular polymeric assemblies, methods of using electroactive supramolecular polymeric assemblies, and the like.
    Type: Grant
    Filed: June 1, 2016
    Date of Patent: May 19, 2020
    Assignee: University of Florida Research Foundation, Inc.
    Inventors: John Hardy, Christine E. Schmidt
  • Patent number: 10639398
    Abstract: The present disclosure provides tissue products produced from extracellular tissue matrices. The tissue products can include acellular extracellular matrices including combinations of different tissue types. The combination can harness various properties of the different tissues to provide improved composite structures with desired mechanical and/or biologic properties.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: May 5, 2020
    Assignee: LifeCell Corporation
    Inventors: Sangwook Park, Hui Xu, Aaron Barere, Israel Jessop, Mrinal Shah, Nathaniel Bachrach
  • Patent number: 10638962
    Abstract: Biocompatible implantable sensor apparatus and methods of implantation and use. In one embodiment, the sensor apparatus is an oxygen-based glucose sensor having biocompatibility features that mitigate the host tissue response. In one variant, these features include use of a non-enzymatic membrane over each of the individual analyte detectors so as to preclude contact of the surrounding tissue with the underlying enzyme or other matrix, and mitigate vascularization, and insulation of the various electrodes and associated electrolytic processes of the sensor from the surrounding tissue. In one implementation, the sensor region of the implanted apparatus is configured to interlock or imprint the surrounding tissue so as to promote a high degree of glucose molecule diffusion into the individual detectors, and a constant and predictable sensor to blood vessel interface, yet preclude the tissue from bonding to the sensor, especially over extended periods of implant.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: May 5, 2020
    Assignee: GlySens Incorporated
    Inventors: Joseph Lucisano, Timothy Routh, Joe Lin
  • Patent number: 10639163
    Abstract: Disclosed is a medical device having a first implant portion having a proximal end, a second implant portion connected to the first implant portion, the second implant portion having a distal end, and a driver assembly removably connected to the distal end, the driver assembly comprising a drill connected to the distal end at a connection.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: May 5, 2020
    Assignee: Tyber Medical, LLC
    Inventors: Jeffrey Tyber, Rui Ferreira, Christopher Faresich, Donald Buss
  • Patent number: 10629096
    Abstract: Described is a group of polymeric calcific heart valves with different levels of calcification that can be used for research and development studies related to transcatheter heart valve technologies. Using a heart flow simulator, the valves' function was studied in aortic position in the presence or absence of an implanted transcatheter aortic valve (valve-in-valve). Through multiple experiments based on echocardiography, it was found that these calcific valves can suitably mimic the function of a native calcified stenotic aortic valve and can be used for valve-in-valve studies. Using this novel polymeric calcified valve provides a desired cost-saving solution for testing the performance of new TAVR systems in vitro and in vivo.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: April 21, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventor: Arash Kheradvar